According to Zacks, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. “
A number of other equities analysts also recently issued reports on AXDX. BTIG Research upgraded Accelerate Diagnostics from a neutral rating to a buy rating in a report on Thursday, August 25th. JPMorgan Chase & Co. increased their price objective on Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an overweight rating in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $25.33.
Accelerate Diagnostics (NASDAQ:AXDX) opened at 27.26 on Tuesday. Accelerate Diagnostics has a one year low of $10.29 and a one year high of $28.50. The company’s market cap is $1.40 billion. The company has a 50-day moving average of $24.42 and a 200-day moving average of $17.37.
Several institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC bought a new position in shares of Accelerate Diagnostics during the second quarter valued at $188,000. American International Group Inc. increased its position in shares of Accelerate Diagnostics by 5.3% in the second quarter. American International Group Inc. now owns 13,263 shares of the company’s stock valued at $191,000 after buying an additional 663 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Accelerate Diagnostics by 11.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,898 shares of the company’s stock valued at $229,000 after buying an additional 1,580 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Accelerate Diagnostics by 25,550.8% in the second quarter. JPMorgan Chase & Co. now owns 16,673 shares of the company’s stock valued at $240,000 after buying an additional 16,608 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Accelerate Diagnostics by 2.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 17,271 shares of the company’s stock valued at $248,000 after buying an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 35.62% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.